)
Shares of Cipla have gained around 1% to Rs 639 on the BSE after the company received approval from United States Food & Drug Administration (USFDA) for an innovative formulation Lopinavir/ritonavir.
Cipla said it has received approval from United States Food & Drug Administration (USFDA) for an innovative formulation Lopinavir/ritonavir (LPV/r) 40mg/10 mg oral pellets — for pediatric specific treatment for infants. This vaccine is prescribed for the treatment of AIDS in infants and young children.
Cipla has long recognized the lack of access to life saving child-friendly formulations for the treatment of HIV, which prompted it to develop an innovative formulation of LPV/r oral pellets. The pellets are to be sprinkled on sweetened porridge for infants and administered to them. The pellets are produced by melt-extrusion technology and are enclosed in capsules.
The stock opened at Rs 639 and touched a high of Rs 644 on the NSE. At 10:40 AM, a total of 238,497 shares changed hands on the counter on the NSE.
